Status:
COMPLETED
Differential Immune Effects of Natalizumab
Lead Sponsor:
Cantonal Hospital of St. Gallen
Conditions:
Multiple Sclerosis, Relapsing Remitting
Eligibility:
All Genders
18-65 years
Brief Summary
Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with...
Detailed Description
Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cel...
Eligibility Criteria
Inclusion
- relapsing remitting MS
- indication for natalizumab treatment
Exclusion
- other disease modifying agents within 2 weeks
Key Trial Info
Start Date :
July 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00859482
Start Date
July 1 2006
End Date
July 1 2007
Last Update
March 11 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.